GYRE vs. XNCR, ANIP, PCRX, KNSA, BLTE, DAWN, DVAX, AKRO, AVDL, and MNKD
Should you be buying Gyre Therapeutics stock or one of its competitors? The main competitors of Gyre Therapeutics include Xencor (XNCR), ANI Pharmaceuticals (ANIP), Pacira BioSciences (PCRX), Kiniksa Pharmaceuticals (KNSA), Belite Bio (BLTE), Day One Biopharmaceuticals (DAWN), Dynavax Technologies (DVAX), Akero Therapeutics (AKRO), Avadel Pharmaceuticals (AVDL), and MannKind (MNKD). These companies are all part of the "pharmaceutical preparations" industry.
Xencor (NASDAQ:XNCR) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, community ranking, media sentiment, valuation, profitability and analyst recommendations.
Xencor currently has a consensus target price of $36.25, suggesting a potential upside of 55.38%. Given Gyre Therapeutics' higher possible upside, equities analysts clearly believe Xencor is more favorable than Gyre Therapeutics.
Xencor received 492 more outperform votes than Gyre Therapeutics when rated by MarketBeat users.
24.0% of Gyre Therapeutics shares are held by institutional investors. 5.2% of Xencor shares are held by insiders. Comparatively, 2.9% of Gyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Xencor had 13 more articles in the media than Gyre Therapeutics. MarketBeat recorded 16 mentions for Xencor and 3 mentions for Gyre Therapeutics. Xencor's average media sentiment score of 0.57 beat Gyre Therapeutics' score of 0.39 indicating that Gyre Therapeutics is being referred to more favorably in the news media.
Gyre Therapeutics has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -82.23%. Gyre Therapeutics' return on equity of -20.29% beat Xencor's return on equity.
Gyre Therapeutics has lower revenue, but higher earnings than Xencor.
Xencor has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 2.13, meaning that its stock price is 113% more volatile than the S&P 500.
Summary
Xencor beats Gyre Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Gyre Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gyre Therapeutics Competitors List
Related Companies and Tools
